Fig. 3

SULT2B1 accelerates CRC cell proliferation and migration by modulating the AKT signaling pathway. A The whole proteins were extracted from pairwise CRC and adjacent tissues, and then immunoblotting was conducted with the indicated antibodies. B Immunoblotting was used to monitor specific molecule expressions in KO-SULT2B1 HT29 and OE-SULT2B1 SW480 cell lines. C Co-immunoprecipitation was performed with Flag primary antibody in OE-SULT2B1 lysates. D Immunofluorescence co-localization was conducted with SULT2B1 and AKT primary antibody (Green dots: SULT2B1; Red dots: t-AKT; Arrow: Yellow dot represent co-localization). E and F GST pull-down assay was carried out, and the interaction between SULT2B1 and AKT was then monitored by gel stain and immunoblotting. G After treatment with SC79 (10 μM hereafter unless otherwise indicated) for 8 h, the lysates were prepared and subjected to immunoblotting with indicated antibodies. H–J MTS assay, colony growth assay (H: 1 μM) and wound healing assay were performed to detect the cell proliferation and migration abilities in cells with SC79 treatments (scale bars = 1 cm and 0.5 mm). K The P21 and P27 expressions were detected by immunoblotting in HT29 cells with the indicated treatments. *P < 0.05 versus control; **P < 0.01 versus control